Edit Entry

Todd W Miller, PhD

Title(s):
Assistant Professor of Pharmacology & Toxicology
Scientific Director, Comprehensive Breast Program, Norris Cotton Cancer Center
Co-Director, Molecular Tumor Board, Norris Cotton Cancer Center

Department(s):
Pharmacology & Toxicology

Education:
University of Connecticut (Storrs, CT), B.S., 1998
University at Albany (Albany, NY), Ph.D. in Biomedical Sciences, 2004

Programs:
Program in Experimental and Molecular Medicine

Websites:
http://geiselmed.dartmouth.edu/miller/
http://www.ncbi.nlm.nih.gov/sites/myncbi/todd.miller.1/bibliography/42064063/public/?sort=date&direction=descending

Contact Information:

1 Medical Center Drive
Rubin Bldg, HB 7936
Lebanon NH 03756

Office: Rubin 604
Phone: 603-653-9284
Fax: 603-653-9952
Email: Todd.W.Miller@Dartmouth.edu


Professional Interests:

Breast cancer, targeted therapeutics, signaling pathways, drug resistance, biomarker development

Rotations and Thesis Projects:

1) Determine the mechanism by which pharmacologic inhibition of Rac GTPase blocks cancer growth.
2) Develop novel, organ-specific models of metastatic breast cancer; determine underlying differences in gene/protein expression and therapeutic sensitivity between tumors in different organs.

Dr. Miller is accepting rotation students in the fall, winter and spring terms and might be available as a thesis mentor for 2016-17 (pending funding).

Grant Information:

RSG-13-292-01-TBE (PI: Miller) 07/01/2013 – 06/30/2017
American Cancer Society
Project: Targeting PI3K and ER pathways in antiestrogen-resistant breast cancer
Role: PI

Career Catalyst Research Grant (PI: Miller) 07/01/2015– 06/30/2018
Susan G. Komen
Project: Estrogen receptor reactivation for treatment of advanced breast cancer
Role: PI

Research Grant (PI: Miller) 07/01/2015 – 06/30/2017
The Mary Kay Foundation
Project: Mechanisms underlying dormancy in ER+ breast cancer
Role: PI

Pilot Project Grant (PI: Miller) 08/01/2014 – no end
Norris Cotton Cancer Center Early-Phase Trials Program
Project: Alternating estradiol and anti-estrogen therapies to prevent disease progression in advanced ER+/HER2- breast cancer.
Role: PI

Investigator-initiated Phase I clinical study (PI: Schwartz)
Takeda Pharmaceuticals 10/01/2015 – 04/30/2017
Project: Phase 1 study of combination of MLN9708 and Fulvestrant in patients with advanced ER+ breast cancer.
Role: Co-Investigator

Research Grant (Co-PIs: Ronan, Miller) 07/01/2014 – no end
The Hitchcock Foundation
Project: Pilot study to develop circulating tumor DNA in cerebrospinal fluid as an early biomarker of leptomeningeal carcinomatosis in patients with metastatic solid tumor cancer.
Role: Co-PI

Program Project Grant Seed Funding (PI: Miller) 11/01/2015 – 10/31/2016
Norris Cotton Cancer Center
Program: Development and management of early-stage breast cancer.
Role: Program Initiator, Co-Leader, and Project 4 PI

Courses Taught:

PEMM 102- Scientific Basis of Disease II
PEMM 126- Cancer Biology
PEMM 132- Clinical Management of Cancer

Biography:

Dr. Miller received his B.S. in Physiology and Neurobiology at the University of Connecticut in 1998, and his Ph.D. in Biomedical Sciences at the State University of New York at Albany in 2004 (thesis: Immunization and single-chain Fv intrabody gene therapies for Huntington’s Disease). He did his postdoctoral training at Vanderbilt University (2004-2009), and served as a Research Faculty member 2009-2012. Dr. Miller joined the Geisel School of Medicine at Dartmouth as an Assistant Professor in 2012.

Mentoring Information:

2012-2014 Lloye Dillon, Ph.D., Postdoctoral Fellow (Current Position: Senior Scientist, Research & Development, OncoTAb, Inc., Charlotte, NC)
2012-present Wei Yang, M.S., PhD Student
2013-present Sarah Hosford, B.S., PhD Student
2014-present Kevin Shee, B.S., MD/PhD student
2015-present Riley Hampsch, B.S., PhD student


Selected Publications: